LL-1 tumor specific genes
| Title: | LL-1 tumor specific genes |
|---|---|
| Patent Number: | 5,811,519 |
| Publication Date: | September 22, 1998 |
| Appl. No: | 08/791,495 |
| Application Filed: | January 27, 1997 |
| Abstract: | The invention describes the LL-1 tumor specific gene family, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LL-1 gene product. |
| Inventors: | Lethe , Bernard (Brussels, BEX); Lucas, Sophie (Brussels, BEX); De Smet, Charles (Brussels, BEX); Godelaine, Daniele (Brussels, BEX); Boon-Falleur, Thierry (Brussels, BEX) |
| Assignees: | Ludwig Institute for Cancer Research (New York, NY) |
| Claim: | We claim |
| Claim: | 1. An isolated polypeptide encoded by an isolated nucleic arid molecule selected from the group consisting of (a) SEQ ID NO:4 and allelic variants thereof, and (b) SEQ ID NO:6 and allelic variants thereof. |
| Claim: | 2. An isolated polypeptide selected from the group consisting of |
| Claim: | (a) a fragment of SEQ ID NO:5 between 5 and 209 consecutive amino acids in length, and |
| Claim: | (b) a fragment of SEQ ID NO:7 between 5 and 179 consecutive amino acids in length. |
| Claim: | 3. The isolated polypeptide of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:4. |
| Claim: | 4. The isolated polypeptide of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:6. |
| Claim: | 5. The isolated polypeptide of claim 2, wherein the isolated polypeptide comprises a fragment of SEQ ID NO:5 between 9 and 209 consecutive amino acids in length. |
| Claim: | 6. The isolated polypeptide of claim 2, wherein the isolated polypeptide comprises a fragment of SEQ ID NO:7 between 9 and 179 consecutive amino acids in length. |
| Claim: | 7. The isolated polypeptide of claim 2, wherein the fragment binds to a polypeptide-binding agent. |
| Claim: | 8. The isolated polypeptide of claim 2, wherein the fragment binds to an antibody or a cytotoxic T lymphocyte. |
| Claim: | 9. The isolated polypeptide of claim 8, wherein the fragment binds to an antibody. |
| Claim: | 10. The isolated polypeptide of claim 8, wherein the fragment binds to a cytotoxic T lymphocyte. |
| Claim: | 11. The isolated polypeptide of claim 2, wherein the isolated polypeptide comprises a fragment of SEQ ID NO:5 between 10 and 209 consecutive amino acids in length. |
| Claim: | 12. The isolated polypeptide of claim 2, wherein the isolated polypeptide comprises a fragment of SEQ ID NO:7 between 10 and 179 consecutive amino acids in length. |
| Claim: | 13. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of(a) SEQ ID NO:5 and allelic variants thereof, and (b) SEQ ID NO:7 and allelic variants thereof. |
| Current U.S. Class: | 530/350; 536/235 |
| Current International Class: | C07K 100; C07K 1400; C07K 1700 |
| Patent References Cited: | 5342774 August 1994 Boon et al. 5405940 April 1995 Boon et al. |
| Other References: | Traversari, et al., Immunogenetics 35:145 (1992). van der Bruggen, et al. Science 254:1643-1647 (1991). Rammensee, et al., Immunogenetics 41:178-228 (1995). Van den Evnde, et al., Curr. Opinion in Immun. 7:674-681 (1995). De Plaen et al., Immunogenetics 40:360-369. (1994). Coulie et al., Stem Cells 13:393-403. (1995). Hubank and Schatz, Nucl. Acids Res. 22:5640. (1994). |
| Primary Examiner: | Huff, Sheela |
| Attorney, Agent or Firm: | Wolf, Greenfield & Sacks, P.C. |
| Accession Number: | edspgr.05811519 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|